Literature DB >> 27178721

Admission Endocan Level may be a Useful Predictor for In-Hospital Mortality and Coronary Severity Index in Patients With ST-Segment Elevation Myocardial Infarction.

Harun Kundi1, Ahmet Balun2, Hulya Cicekcioglu2, Orhan Karayigit2, Canan Topcuoglu3, Muhammed Fevzi Kilinckaya3, Emrullah Kiziltunc2, Mustafa Cetin2, Ender Ornek2.   

Abstract

We assessed the prognostic role of serum endocan level in patients with ST-segment elevation myocardial infarction (STEMI) and compared the results with a normal coronary angiography group. A total of 133 patients were included in the study (88 patients with STEMI and 45 patients with normal coronary arteries). The SYNTAX score was determined based on the baseline coronary angiogram. Multivariate logistic regression analysis indicated that endocan independently correlated with the presence of STEMI. Moreover, high-sensitivity C-reactive protein (hsCRP), peak troponin I, and left ventricular ejection fraction (LVEF) were found to be independently associated with STEMI. Endocan level correlated significantly with hsCRP and SYNTAX score. We analyzed the discriminatory capability of endocan level for the presence of STEMI using a receiver-operating characteristics curve. A cutoff endocan level of 1.7 (ng/mL) predicted the presence of STEMI with a sensitivity of 76.1% and specificity of 73.6%. In conclusion, a high endocan level on hospital admission is an independent predictor of a worse cardiovascular outcome and a high SYNTAX score in patients with STEMI.
© The Author(s) 2016.

Entities:  

Keywords:  STEMI; SYNTAX score; endocan; inflammation

Mesh:

Substances:

Year:  2016        PMID: 27178721     DOI: 10.1177/0003319716646932

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  9 in total

1.  Serum endocan levels in patients with cardiac syndrome X.

Authors:  S C Efe; K Demirci; S Ozturk; A S Gurbuz; N Poci; A Kilicgedik; A Guler; M F Yilmaz; I A İzgi; C Kirma
Journal:  Herz       Date:  2017-06-06       Impact factor: 1.443

2.  Association of Biomarker Level with Cardiovascular Events: Results of a 4-Year Follow-Up Study.

Authors:  L Turgunova; B Baidildina; Y Laryushina; B Koichubekov; A Turmukhambetova; L Akhmaltdinova
Journal:  Cardiol Res Pract       Date:  2020-06-23       Impact factor: 1.866

Review 3.  Methods to evaluate vascular function: a crucial approach towards predictive, preventive, and personalised medicine.

Authors:  Cristina M Sena; Lino Gonçalves; Raquel Seiça
Journal:  EPMA J       Date:  2022-05-20       Impact factor: 8.836

4.  The higher serum endocan levels may be a risk factor for the onset of cardiovascular disease: A meta-analysis.

Authors:  Tianming Zhao; Yao Kecheng; Xuelei Zhao; Xuehua Hu; Jing Zhu; Yingnan Wang; Jixiang Ni
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 5.  The Biomarkers for Acute Myocardial Infarction and Heart Failure.

Authors:  Xi-Ying Wang; Fen Zhang; Chi Zhang; Liang-Rong Zheng; Jian Yang
Journal:  Biomed Res Int       Date:  2020-01-17       Impact factor: 3.411

Review 6.  Endocan: A Key Player of Cardiovascular Disease.

Authors:  Jinzhi Chen; Liping Jiang; Xiao-Hua Yu; Mi Hu; Yang-Kai Zhang; Xin Liu; Pingping He; Xinping Ouyang
Journal:  Front Cardiovasc Med       Date:  2022-01-05

7.  Serum Endocan Levels Predict Drug-Eluting Stent Restenosis in Patients with Stable Angina Pectoris.

Authors:  Ayhan Küp; Cüneyt Toprak; Emrah Bayam; Servet İzcı; Abdulkadir Uslu; Mehmet Çelık; İsmail Balaban; Sinan Cerşıt; Süleyman Barutçu; Pınar Demir Gündoğmuş
Journal:  Acta Cardiol Sin       Date:  2020-03       Impact factor: 2.672

8.  Endocan expression is correlated with poor progression-free survival in patients with pancreatic neuroendocrine tumors.

Authors:  Liang-Yu Lin; Yi-Chen Yeh; Chia-Huei Chu; Justin G S Won; Yi-Ming Shyr; Yee Chao; Chung-Pin Li; Shin-E Wang; Ming-Huang Chen
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817

9.  Comparative effects of atorvastatin 80 mg and rosuvastatin 40 mg on the levels of serum endocan, chemerin, and galectin-3 in patients with acute myocardial infarction.

Authors:  Abdullah Tunçez; Bülent Behlül Altunkeser; Bahadır Öztürk; Muhammed Salih Ateş; Hüseyin Tezcan; Canan Aydoğan; Emre Can Kırık; Ulvi Yalçın; Nazif Aygül; Kenan Demir; Fikret Akyürek
Journal:  Anatol J Cardiol       Date:  2019-11       Impact factor: 1.596

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.